Brett Zbar, MD, is a Managing Director and Global Head of Life Sciences at General Atlantic, a global growth equity firm. General Atlantic invests broadly across the life sciences sector, including therapeutics, life science tools, and pharmaceutical services. He currently serves on the board of Javara, an integrated clinical research services organization, Verdiva Bio, a drug development company focused on obesity and cardiometabolic disease, and Centessa Pharmaceuticals, a publicly-traded drug development company. Prior to joining General Atlantic in 2020, Brett was a Managing Director at Foresite Capital, where he focused on backing leading healthcare entrepreneurs and companies at all stages. While at Foresite, Brett served as a board member or observer at multiple companies including ConnectiveRx, Kinnate Biopharma, ORIC Pharmaceuticals (IPO), Peloton Therapeutics (acquired), Pharvaris (IPO), Replimune (IPO), Signant Health, Turning Point Therapeutics (IPO) and VenatoRx Pharmaceuticals. Prior to that, he was a Partner at Aisling Capital, where he invested in companies developing and commercializing innovative healthcare products, services and technologies.

Earlier in his career Brett was an Associate Principal in McKinsey & Company’s Pharmaceuticals and Medical Products practice, where he served pharmaceutical, biotechnology and private equity clients. He completed his internship in internal medicine on the Osler Medical Service at Johns Hopkins Hospital. Brett received his MD from Harvard Medical School, and earned a BA in English and Molecular Biophysics & Biochemistry from Yale College. He previously served as Chair of the Yale Alumni Fund Board of Directors, and is a life member of the Council on Foreign Relations.